Research Analysts Issue Forecasts for Omeros FY2025 Earnings

Omeros Co. (NASDAQ:OMER - Free Report) - Research analysts at Cantor Fitzgerald decreased their FY2025 EPS estimates for shares of Omeros in a research note issued on Wednesday, April 2nd. Cantor Fitzgerald analyst O. Brayer now expects that the biopharmaceutical company will post earnings per share of ($2.19) for the year, down from their previous forecast of ($1.73). The consensus estimate for Omeros' current full-year earnings is ($3.09) per share. Cantor Fitzgerald also issued estimates for Omeros' FY2025 earnings at ($2.19) EPS.

Omeros (NASDAQ:OMER - Get Free Report) last announced its quarterly earnings data on Monday, March 31st. The biopharmaceutical company reported ($0.63) earnings per share for the quarter, beating the consensus estimate of ($0.71) by $0.08. During the same quarter last year, the business posted ($0.15) EPS.

A number of other brokerages have also recently issued reports on OMER. D. Boral Capital reiterated a "buy" rating and issued a $36.00 target price on shares of Omeros in a report on Tuesday, April 1st. StockNews.com lowered shares of Omeros from a "hold" rating to a "sell" rating in a research note on Wednesday. Finally, Needham & Company LLC reissued a "hold" rating on shares of Omeros in a research report on Tuesday, April 1st. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, two have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $22.50.

Omeros Stock Up 6.7 %

NASDAQ:OMER traded up $0.40 on Friday, hitting $6.43. The stock had a trading volume of 934,544 shares, compared to its average volume of 559,356. Omeros has a 52 week low of $2.97 and a 52 week high of $13.60. The business's fifty day moving average is $8.40 and its 200 day moving average is $7.70. The company has a market cap of $373.41 million, a PE ratio of -2.80 and a beta of 2.35.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in OMER. Truvestments Capital LLC increased its stake in Omeros by 116.5% in the 4th quarter. Truvestments Capital LLC now owns 3,102 shares of the biopharmaceutical company's stock valued at $31,000 after buying an additional 1,669 shares during the last quarter. Tower Research Capital LLC TRC grew its holdings in shares of Omeros by 79.0% in the fourth quarter. Tower Research Capital LLC TRC now owns 4,467 shares of the biopharmaceutical company's stock valued at $44,000 after acquiring an additional 1,972 shares in the last quarter. Quantbot Technologies LP purchased a new stake in shares of Omeros during the fourth quarter valued at approximately $46,000. BNP Paribas Financial Markets lifted its holdings in Omeros by 130.6% during the third quarter. BNP Paribas Financial Markets now owns 12,388 shares of the biopharmaceutical company's stock worth $49,000 after acquiring an additional 7,016 shares during the period. Finally, Picton Mahoney Asset Management boosted its position in Omeros by 692.5% in the fourth quarter. Picton Mahoney Asset Management now owns 5,040 shares of the biopharmaceutical company's stock worth $50,000 after purchasing an additional 4,404 shares during the last quarter. 48.79% of the stock is owned by institutional investors.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.